The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors

American Journal of Cardiology

Volumn 104, Issue 10 SUPPL., 2009, Pages 32E-38E

  Vergeer, Menno ^a   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INHIBITION KINETICS; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 71749117374     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.09.017     Document Type: Article

References (45)

1. Rader D.J. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 4 (2007) 102-109
2. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
3. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., and Tall A.R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
4. Curb J.D., Abbott R.D., Rodriguez B.L., Masaki K., Chen R., Sharp D.S., and Tall A.R. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45 (2004) 948-953
5. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sakai N., Kameda-Takemura K., and Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17 (1997) 1053-1059
6. Thompson A., Di Angelantonio E., Sarwar N., Erqou S., Saleheen D., Dullaart R.P.F., Keavney B., Ye Z., and Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299 (2008) 2777-2788
7. Rennings A.J., and Stalenhoef A.F. JTT-705: is there still future for a CETP inhibitor after torcetrapib?. Expert Opin Investig Drugs 17 (2008) 1589-1597
8. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., and Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19 (1999) 1105-1110
9. Westerterp M., van der Hoogt C.C., de Haan W., Offerman E.H., Dallinga-Thie G.M., Jukema J.W., Havekes L.M., and Rensen P.C. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2552-2559
10. Herrera V.L., Makrides S.C., Xie H.X., Adari H., Krauss R.M., Ryan U.S., and Ruiz-Opazo N. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 5 (1999) 1383-1389
11. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., and Tall A.R. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 96 (1995) 2071-2074
12. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., Fruchart-Najib J., Paiz J.A., Koch C.A., Hoyt R.F., Brewer Jr. H.B., and Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 274 (1999) 36912-36920
13. Harder C., Lau P., Meng A., Whitman S.C., and McPherson R. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 858-864
14. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., Kamada M., and Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273 (1998) 5033-5036
15. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2106-2112
16. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
17. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
18. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van T.A., and Kastelein J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
19. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., Trip M.D., and Kastelein J.J. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95 (2005) 1085-1088
20. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., Mancuso J.P., and Rader D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
21. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., Cosgrove P.G., Sand T.M., Wester R.T., Williams J.A., Perlman M.E., and Bamberger M.J. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
22. McKenney J.M., Davidson M.H., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48 (2006) 1782-1790
23. Davidson M.H., McKenney J.M., Shear C.L., and Revkin J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 48 (2006) 1774-1781
24. Bots M.L., Visseren F.L., Evans G.W., Riley W.A., Revkin J.H., Tegeler C.H., Shear C.L., Duggan W.T., Vicari R.M., Grobbee D.E., and Kastelein J.J. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
25. Kastelein J.J.P., van Leuven S.I., Burgess L., Evans G.W., Kuivenhoven J.A., Barter P.J., Revkin J.H., Grobbee D.E., Riley W.A., Shear C.L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
26. Nissen S.E., Tardif J.C., Nicholls S.J., Revkin J.H., Shear C.L., Duggan W.T., Ruzyllo W., Bachinsky W.B., Lasala G.P., Tuzcu E.M., and ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
27. Guerin M., Le Goff W., Duchene E., Julia Z., Nguyen T., Thuren T., Shear C.L., and Chapman M.J. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 28 (2008) 148-154
28. Krishna R., Bergman A.J., Jin B., Fallon M., Cote J., Van Hoydonck P., Laethem T., Gendrano III I.N., Van Dyck K., Hilliard D., et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 84 (2008) 679-683
29. Krishna R., Anderson M.S., Bergman A.J., Jin B., Fallon M., Cote J., Rosko K., Chavez-Eng C., Lutz R., Bloomfield D.M., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370 (2008) 1907-1914
30. Bloomfield D., Carlson G.L., Sapre A., Tribble D., McKenney J.M., Littlejohn III T.W., Sisk C.M., Mitchel Y., and Pasternak R.C. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157 (2009) 352-360
31. Shinkai H., Maeda K., Yamasaki T., Okamoto H., and Uchida I. bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem 43 (2000) 3566-3572
32. Huang Z., Inazu A., Nohara A., Higashikata T., and Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 103 (2002) 587-594
33. Clark R.W., Ruggeri R.B., Cunningham D., and Bamberger M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47 (2006) 537-552
34. Morehouse L.A., Sugarman E.D., Bourassa P.A., Sand T.M., Zimetti F., Gao F., Rothblat G.H., and Milici A.J. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48 (2007) 1263-1272
35. de Haan W., de Vries-van der Weij J., van der Hoorn J.W., Gautier T., van der Hoogt C.C., Westerterp M., Romijn J.A., Jukema J.W., Havekes L.M., Princen H.M., and Rensen P.C. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 117 (2008) 2515-2522
36. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., Cosgrove P.G., Sand T.M., Wester R.T., Williams J.A., Perlman M.E., and Bamberger M.J. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
37. O'Neill E., Sparrow C.P., Chen Y., Frantz-Wattley B., Milot D., Sinclair P.J., Ali A., Lu Z., Smith C.J., Taylor G., et al. Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor. [abstract]. Presented at the XVI International Symposium on Drugs Affecting Lipid Metabolism; October 4-7, New York, New York. (2007)
38. Vergeer M., Bots M.L., van Leuven S.I., Basart D.C., Sijbrands E.J., Evans G.W., Grobbee D.E., Visseren F.L., Stalenhoef A.F., Stroes E.S., and Kastelein J.J. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118 (2008) 2515-2522
39. Nicholls S.J., Tuzcu E.M., Brennan D.M., Tardif J.C., and Nissen S.E. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118 (2008) 2506-2514
40. Forrest M.J., Bloomfield D., Briscoe R.J., Brown P.N., Cumiskey A.M., Ehrhart J., Hershey J.C., Keller W.J., Ma X., McPherson H.E., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154 (2008) 1465-1473
41. Hu X., Dietz J.D., Xia C., Knight D.R., Loging W.T., Smith A.H., Yuan H., Perry D.A., and Keiser J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150 (2009) 2211-2219
42. Stroes E.S., Kastelein J.J., Bernardeau A., Blum D., Clerc R.G., Campos L., and Niesor E. Absence of effect of R1658/JTT-705 on blood pressure and tissue expression of renin-angiotensin system related genes in rats [abstract]. J Am Coll Cardiol 51 suppl 1 (2008) A322
43. Stein E.A., Kallend D., and Buckley B. Safety profile of the cholesteryl ester transfer protein inhibitor R1658/JTT-705 in patients with type II hyperlipidemia or coronary heart disease [abstract]. J Am Coll Cardiol 51 suppl 1 (2008) A333-A334
44. Steiner G., Kastelein J.J., Kallend D., and Stroes E.S. Cardiovascular safety of the cholesteryl ester transfer protein inhibitor R1658/JTT-705: results from phase 2 trials [abstract]. J Am Coll Cardiol 51 suppl 1 (2008) A333
45. Funder J.W. The off-target effects of torcetrapib. Endocrinology 150 (2009) 2024-2026